PE20081686A1 - Proteinas de fusion que comprenden un antigeno prame (dage) - Google Patents
Proteinas de fusion que comprenden un antigeno prame (dage)Info
- Publication number
- PE20081686A1 PE20081686A1 PE2008000124A PE2008000124A PE20081686A1 PE 20081686 A1 PE20081686 A1 PE 20081686A1 PE 2008000124 A PE2008000124 A PE 2008000124A PE 2008000124 A PE2008000124 A PE 2008000124A PE 20081686 A1 PE20081686 A1 PE 20081686A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- same
- antigen
- derlusina
- alyvdslffligion
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000036673 PRAME Human genes 0.000 title 1
- 108060006580 PRAME Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 abstract 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 abstract 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 abstract 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 abstract 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 abstract 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 abstract 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 abstract 1
- 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 abstract 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 abstract 1
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 abstract 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 abstract 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 abstract 1
- 102100025081 Melanoma-associated antigen 2 Human genes 0.000 abstract 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 abstract 1
- DNDVVILEHVMWIS-LPEHRKFASA-N Met-Asp-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DNDVVILEHVMWIS-LPEHRKFASA-N 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000003425 Tyrosinase Human genes 0.000 abstract 1
- 108060008724 Tyrosinase Proteins 0.000 abstract 1
- 102100022748 Wilms tumor protein Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: A) EL ANTIGENO DE RECHAZO TUMORAL DENOMINADO PRAME O UN FRAGMENTO DEL MISMO QUE CONSTA DE LOS SIGUIENTES EPITOPES: VLDGLDVLL, SLYSFPEPEA, ALYVDSLFFL, LYVDSLFFL, SLLQHLIGL, B) UNA PROTEINA PAREJA DE FUSION DERIVADA DE PROTEINA D, TAL COMO MAGE1, MAGE2, MAGEC2, ENTRE OTROS, QUE CONTIENE 20 A 127 AMINOACIDOS DE LA PROTEINA D. TAMBIEN SE REFIERE A UNA SECUENCIA SENAL DE PROTEINA D LA CUAL CONTIENE 19 AMINOACIDOS N-TERMINALES DE LA MISMA, UNA SECUENCIA DE ACIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, UNA CELULA HUESPED, PROCEDIMIENTO DE PREPARACION DE LAS MISMAS Y UNA VACUNA. DICHA PROTEINA DE FUSION ES CAPAZ DE DIRIGIR UNA RESPUESTA AL ANTIGENO: WT-1, BAGE, LAGE1, NY-ESO-1, TIROSINASA, ENTRE OTROS, TIENE Met-Asp-Pro EN EL EXTREMO N-TERMINAL Y ES DE UTILIDAD EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700760A GB0700760D0 (en) | 2007-01-15 | 2007-01-15 | Vaccine |
| GB0701262A GB0701262D0 (en) | 2007-01-23 | 2007-01-23 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081686A1 true PE20081686A1 (es) | 2008-12-25 |
Family
ID=39300029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000124A PE20081686A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
| PE2012001372A PE20130324A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001372A PE20130324A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20080187535A1 (es) |
| EP (1) | EP2114993B1 (es) |
| JP (1) | JP5391080B2 (es) |
| KR (1) | KR20090101313A (es) |
| CN (1) | CN101668770B (es) |
| AR (1) | AR064862A1 (es) |
| AU (1) | AU2008207025B2 (es) |
| BR (1) | BRPI0806463A2 (es) |
| CA (1) | CA2674552A1 (es) |
| CL (1) | CL2008000104A1 (es) |
| CO (1) | CO6210757A2 (es) |
| CR (1) | CR10971A (es) |
| CY (1) | CY1113760T1 (es) |
| DK (1) | DK2114993T3 (es) |
| DO (1) | DOP2009000167A (es) |
| EA (1) | EA016326B1 (es) |
| ES (1) | ES2393812T3 (es) |
| HR (1) | HRP20120828T1 (es) |
| IL (1) | IL199663A0 (es) |
| JO (1) | JO2840B1 (es) |
| MA (1) | MA31093B1 (es) |
| MX (1) | MX2009007571A (es) |
| MY (1) | MY153679A (es) |
| NZ (1) | NZ578285A (es) |
| PE (2) | PE20081686A1 (es) |
| PL (1) | PL2114993T3 (es) |
| PT (1) | PT2114993E (es) |
| SI (1) | SI2114993T1 (es) |
| TW (1) | TWI434697B (es) |
| WO (1) | WO2008087102A1 (es) |
| ZA (1) | ZA200904923B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2674458A1 (en) * | 2007-01-15 | 2008-07-24 | Glaxosmithkline Biologicals S.A. | Fusion protein |
| AU2010225125A1 (en) | 2009-03-17 | 2011-10-20 | Glaxosmithkline Biologicals S.A. | Improved detection of gene expression |
| EP2438173A4 (en) * | 2009-06-05 | 2012-10-31 | Univ Ohio State Res Found | BIOMATERIALS, COMPOSITIONS AND METHODS |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| GB201008682D0 (en) * | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| CA2841380A1 (en) * | 2011-07-22 | 2013-01-31 | Glaxosmithkline Biologicals S.A. | Prame purification |
| GB201114919D0 (en) * | 2011-08-30 | 2011-10-12 | Glaxosmithkline Biolog Sa | Method |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| RU2590701C2 (ru) * | 2013-04-29 | 2016-07-10 | Общество с ограниченной ответственностью "ГеноТехнология" | Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка |
| JP6558699B2 (ja) | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン |
| CN105254767A (zh) * | 2015-11-17 | 2016-01-20 | 重庆科润生物医药研发有限公司 | 一种Protein D与HER2融合蛋白及其制备方法和应用 |
| JP7197481B2 (ja) | 2016-11-30 | 2022-12-27 | アドバクシス， インコーポレイテッド | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 |
| CN108264550B (zh) * | 2017-01-04 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别源自于prame抗原短肽的tcr |
| CN108948184B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别衍生自prame抗原短肽的t细胞受体 |
| CN109400697B (zh) * | 2017-08-17 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别prame抗原短肽的tcr及其相关组合物 |
| WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
| AU2018366131A1 (en) * | 2017-11-08 | 2020-05-28 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
| CN109879957B (zh) * | 2017-12-06 | 2022-03-18 | 香雪生命科学技术（广东）有限公司 | 针对prame的高亲和力t细胞受体 |
| US20230190902A1 (en) * | 2020-05-29 | 2023-06-22 | Children's National Medical Center | Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2156718A1 (en) * | 1993-12-23 | 1995-06-29 | Bruno Gander | Immunological response potentiation process |
| US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| ATE315088T1 (de) * | 1998-02-05 | 2006-02-15 | Glaxosmithkline Biolog Sa | Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung |
| CA2363118A1 (en) * | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
| AU5821000A (en) * | 1999-06-29 | 2001-01-31 | Smithkline Beecham Biologicals (Sa) | Vaccine |
| CA2378097A1 (en) * | 1999-07-08 | 2001-01-18 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
-
2008
- 2008-01-11 BR BRPI0806463-6A patent/BRPI0806463A2/pt not_active IP Right Cessation
- 2008-01-11 CA CA002674552A patent/CA2674552A1/en not_active Abandoned
- 2008-01-11 WO PCT/EP2008/050290 patent/WO2008087102A1/en not_active Ceased
- 2008-01-11 MY MYPI20092932A patent/MY153679A/en unknown
- 2008-01-11 AU AU2008207025A patent/AU2008207025B2/en not_active Ceased
- 2008-01-11 TW TW097101177A patent/TWI434697B/zh not_active IP Right Cessation
- 2008-01-11 HR HRP20120828AT patent/HRP20120828T1/hr unknown
- 2008-01-11 ES ES08701434T patent/ES2393812T3/es active Active
- 2008-01-11 DK DK08701434.6T patent/DK2114993T3/da active
- 2008-01-11 PL PL08701434T patent/PL2114993T3/pl unknown
- 2008-01-11 PE PE2008000124A patent/PE20081686A1/es not_active Application Discontinuation
- 2008-01-11 EP EP08701434A patent/EP2114993B1/en not_active Not-in-force
- 2008-01-11 US US12/013,011 patent/US20080187535A1/en not_active Abandoned
- 2008-01-11 KR KR1020097017027A patent/KR20090101313A/ko not_active Ceased
- 2008-01-11 AR ARP080100127A patent/AR064862A1/es active IP Right Grant
- 2008-01-11 EA EA200900795A patent/EA016326B1/ru not_active IP Right Cessation
- 2008-01-11 SI SI200830787T patent/SI2114993T1/sl unknown
- 2008-01-11 PT PT08701434T patent/PT2114993E/pt unknown
- 2008-01-11 NZ NZ578285A patent/NZ578285A/en not_active IP Right Cessation
- 2008-01-11 MX MX2009007571A patent/MX2009007571A/es active IP Right Grant
- 2008-01-11 PE PE2012001372A patent/PE20130324A1/es not_active Application Discontinuation
- 2008-01-11 JP JP2009545186A patent/JP5391080B2/ja not_active Expired - Fee Related
- 2008-01-11 CN CN2008800078884A patent/CN101668770B/zh not_active Expired - Fee Related
- 2008-01-13 JO JO200815A patent/JO2840B1/en active
- 2008-01-14 CL CL200800104A patent/CL2008000104A1/es unknown
-
2009
- 2009-07-02 DO DO2009000167A patent/DOP2009000167A/es unknown
- 2009-07-02 IL IL199663A patent/IL199663A0/en unknown
- 2009-07-10 MA MA32087A patent/MA31093B1/fr unknown
- 2009-07-14 ZA ZA2009/04923A patent/ZA200904923B/en unknown
- 2009-07-15 CO CO09073705A patent/CO6210757A2/es not_active Application Discontinuation
- 2009-08-07 CR CR10971A patent/CR10971A/es unknown
-
2012
- 2012-11-09 CY CY20121101065T patent/CY1113760T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| EA202192570A1 (ru) | Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| CL2018003148A1 (es) | Proteínas de fusión y usos de las mismas. | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
| CO2017004838A2 (es) | Vacunas terapéuticas contra el vph16 | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| AR078423A1 (es) | Vacunas dirigidas a las celulas de langerhans | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| MX2018013081A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
| CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
| CY1125448T1 (el) | Μεθοδοι για την ενισχυμενη αφαιρεση προσμειξεων κατα τη διαρκεια χρωματογραφιας πρωτεϊνης α |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |